Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
May 30, 2024 8:00 AM 5 min read

What Analysts Are Saying About CVS Health Stock

by Benzinga Insights Benzinga Staff Writer
Follow
FlipboardIcon version of the Flipboard logo

CVS Health (NYSE:CVS) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 5 3 9 0 0
Last 30D 0 0 1 0 0
1M Ago 5 0 6 0 0
2M Ago 0 2 1 0 0
3M Ago 0 1 1 0 0

Analysts have set 12-month price targets for CVS Health, revealing an average target of $71.29, a high estimate of $94.00, and a low estimate of $58.00. This current average has decreased by 19.06% from the previous average price target of $88.08.

Interpreting Analyst Ratings: A Closer Look

A comprehensive examination of how financial experts perceive CVS Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Capture valuable insights into CVS Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on CVS Health analyst ratings.

About CVS Health

CVS Health's Financial Performance

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: CVS Health's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 3.7%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: CVS Health's net margin is impressive, surpassing industry averages. With a net margin of 1.26%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): CVS Health's ROE stands out, surpassing industry averages. With an impressive ROE of 1.48%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): CVS Health's ROA stands out, surpassing industry averages. With an impressive ROA of 0.45%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: With a below-average debt-to-equity ratio of 1.11, CVS Health adopts a prudent financial strategy, indicating a balanced approach to debt management.

The Basics of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Analyst RatingsBZI-AAR
CVS Logo
CVSCVS Health Corp
$78.710.02%
Overview
Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Michael Ha Baird Announces Neutral $61.00 -
Chris Graja Argus Research Lowers Buy $80.00 $100.00
Stephen Baxter Wells Fargo Lowers Equal-Weight $60.00 $76.00
Charles Ryhee TD Cowen Lowers Hold $59.00 $99.00
Michael Cherny B of A Securities Lowers Buy $77.00 $95.00
Nathan Rice Goldman Sachs Lowers Buy $74.00 $85.00
Andrew Mok Barclays Lowers Equal-Weight $63.00 $78.00
Kevin Caliendo UBS Lowers Neutral $60.00 $85.00
David Macdonald Truist Securities Lowers Buy $66.00 $90.00
Ann Hynes Mizuho Lowers Buy $72.00 $86.00
Michael Cherny Leerink Partners Announces Market Perform $60.00 -
Sarah James Cantor Fitzgerald Lowers Neutral $58.00 $87.00
Sarah James Cantor Fitzgerald Maintains Overweight $87.00 -
Stephen Baxter Wells Fargo Lowers Equal-Weight $76.00 $83.00
Sarah James Cantor Fitzgerald Maintains Overweight $87.00 -
Jessica Tassan Piper Sandler Raises Overweight $94.00 $93.00
Andrew Mok Barclays Announces Equal-Weight $78.00 -
  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CVS Health compared to the broader market.
  • Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CVS Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.

CVS Logo
CVSCVS Health Corp
$78.710.02%
Overview
Comments
Loading...